BONUS: Breaking Down The Latest Anti-Trans Victory Lap

Evidence Analysis

The discussion on gender dysphoria evidence highlights the complexity of medical interventions and the strength of existing studies. Michael Hobbes points out that while the evidence is often labeled as low quality, this is common in many medical fields where treatments are still being evaluated for effectiveness and safety 1. He emphasizes that the field is cautious, with only a small number of children receiving hormones or puberty blockers annually. Aubrey Gordon adds that most medical treatments involve calculated risks, similar to everyday medications like ibuprofen 1.

Most, if not all, medical treatments are some level of calculated risk. Right. Even when you take an advil, if you're taking ibuprofen, that's, like, hard on your kidneys.

--- Aubrey Gordon

The conversation also touches on the positive outcomes of gender transition studies, noting significant decreases in anxiety, suicidality, and depression among participants 2.

   

Research and Debate

The podcast explores the insights from transgender research and the ongoing debate over puberty blockers. Michael Hobbes critiques the dismissal of studies on social transition, arguing that the evidence is often misrepresented or undervalued 3. He stresses that trans people have a vested interest in understanding the best care practices, contrary to claims that they oppose research. Aubrey Gordon echoes this sentiment, highlighting the lack of institutional support for transgender research 3.

Trans people very much want to know what is the best pathway for people? What are the best dosages? What are the side effects?

--- Michael Hobbes

In discussing puberty blockers, Hobbes notes that while there are limited studies, the existing research suggests either neutral or positive outcomes for transgender youth 4. He argues that the lack of negative findings supports the continued use of puberty blockers, despite the limited data.